October Term 2012 · Docket 12-142

Can generic drug makers face design-defect liability despite FDA approval?

The dispute centers on whether federal law blocks state design-defect claims against generic drug manufacturers.

Official caption
Mutual Pharmaceutical Co. v. Bartlett
Latest argument session
Latest official Court activity
Latest verified event
Argued
Sources analyzed through
Official Transcript

Verified source milestones

  1. — An official oral-argument transcript was verified.

The arguments, in order

This case may have been argued more than once. Each entry below uses that session's official transcript. Later arguments do not erase earlier ones.

  1. Argument 1 ·

    What happened at the argument

    Mutual Pharmaceutical argues federal law requires identical ingredients and warnings.

    Bartlett argues New Hampshire law imposes a hybrid design-defect standard.

    Justice Sotomayor questioned whether FDA approval creates an absolute liability shield.

    Justice Kagan asked how the argument applies to brand-named drugs.

    Read the official transcript for this argument · Official argument details

    Sources used for this argument breakdown

A citizen's guide to the whole case

What this case is about

This case tests the scope of federal preemption for generic drugs.

Official sources for this section

How the case got here

The Supreme Court heard oral argument in this case on March 19, 2013.

Official sources for this section

What each side wants

Mutual Pharmaceutical seeks dismissal of the state design-defect claim.

Bartlett seeks to maintain the state design-defect claim.

Official sources for this section

What each side says

Mutual Pharmaceutical argues federal law preempts state design-defect claims.

Bartlett argues state law imposes a distinct design-defect duty.

Official sources for this section

What the justices asked

Justice Sotomayor asked if FDA approval bars all tort claims.

Justice Kagan asked about the scope of the argument for brand drugs.

Official sources for this section

Why it matters

This case defines the boundary between federal drug regulation and state tort law.

Official sources for this section

What happens next

This article currently covers the argument record. Use the official docket link for later case activity.

Official sources for this section

Official Court provenance

Official docket and case history · Official Supreme Court oral-argument detail page

Title and summary sources

Revision history

  1. Revision 1 · Official Transcript ·

    Correction: Rewritten to the concise citizen-facing editorial standard.

  2. Revision 2 · Official Transcript ·

    Correction: Migrated to the dated official Court activity contract without model use.

Download this sanitized case as JSON